129 related articles for article (PubMed ID: 32981794)
1. Primary site disease and recurrence location in ovarian cancer patients undergoing primary debulking surgery vs. interval debulking surgery.
Vito Andrea C; Uccella S; Sozzi G; Ceccaroni M; Mautone D; Armano G; Franchi M; Chiantera V; Berretta R
Eur J Surg Oncol; 2021 May; 47(5):1075-1082. PubMed ID: 32981794
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
3. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
[TBL] [Abstract][Full Text] [Related]
5. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
6. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
7. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
[TBL] [Abstract][Full Text] [Related]
8. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
9. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
10. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery.
Paik ES; Lee YY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):639-647. PubMed ID: 27611447
[TBL] [Abstract][Full Text] [Related]
11. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.
Makar AP; Tropé CG; Tummers P; Denys H; Vandecasteele K
Oncologist; 2016 Jun; 21(6):745-54. PubMed ID: 27009938
[TBL] [Abstract][Full Text] [Related]
12. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.
Petrillo M; Ferrandina G; Fagotti A; Vizzielli G; Margariti PA; Pedone AL; Nero C; Fanfani F; Scambia G
Ann Surg Oncol; 2013 Nov; 20(12):3955-60. PubMed ID: 23838915
[TBL] [Abstract][Full Text] [Related]
13. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
14. Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma.
Lee EYP; An H; Perucho JAU; Chiu KWH; Hui ES; Chu MMY; Ngan HYS
Eur Radiol; 2020 Oct; 30(10):5551-5559. PubMed ID: 32405751
[TBL] [Abstract][Full Text] [Related]
15. Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study.
Glover O; Asher V; Bali A; Abdul S; Collins A; Phillips A
Anticancer Res; 2020 Jul; 40(7):3925-3929. PubMed ID: 32620633
[TBL] [Abstract][Full Text] [Related]
16. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
17. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
18. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
[TBL] [Abstract][Full Text] [Related]
19. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
20. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
